| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
3 companies
Third Rock Ventures LP last filed a Form 4 in August 2018, as 10% Owner at CTMX. The filings on record cover 3 companies.
At the last filing, the largest reported position was 2,981,437 shares of RYTM.
Third Rock Ventures LP has 11 Form 4 filings on record from March 2015 to August 2018, across 3 companies: 10% Owner at Rhythm Pharmaceuticals (RYTM), 2017–2018; 10% Owner at CytomX Therapeutics (CTMX), 2015–2017; 10% Owner at Larimar Therapeutics (LRMR), 2015.
The 18 reported transactions were 14 other transactions, 2 conversions and 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $28.7M.
The only open-market sale was 1,650,000 shares of CTMX at an average $17.39 on March 27, 2017, about $28.7M.
Shares as reported in the last Form 4 for each company; the most recent is from August 2018. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 27, 2017 | CTMX Cytomx Therapeutics, Inc. | 10% Owner | Sell | 1,650,000 | $17.39 | $28,700,395.00 | -24.2% |